肾内及风湿免疫类药物超药品说明书用药专家共识[山东省超药品说明书用药专家共识(2022版)系列]  

Expert Consensus on Off-Label Drug Use of Shandong Province (2022 Edition):for Intrarenal and Rheumatic Immune Drugs

作　　者：梁传鹏 赵丽霞[1,2] 刘敏 侯宁[2,3] LIANG Chuan-peng;ZHAO Li-xia;LIU Min;HOU Ning(Department of Pharmacy,Qilu Hospital of Shandong University,Jinan 250012,China;Evidence-Based Pharmacy Specialites of Shandong Pharmaceutical Association,Jinan 250021,China;Department of Pharmacy,Shandong Provincial Hospital Affiliated to Shandong First Medical University,Jinan 250021,China)

机构地区：[1]山东大学齐鲁医院药剂科,济南250012 [2]山东省药学会循证药学专业委员会,济南250021 [3]山东第一医科大学附属省立医院药学部,济南250021

出　　处：《中国合理用药探索》2023年第3期37-43,共7页Chinese Journal of Rational Drug Use

摘　　要：风湿免疫疾病的诊疗手段日新月异,不断涌现的新型免疫抑制剂为免疫性疾病的临床治疗开创了新格局。同时,该领域药品说明书更新滞后于临床实践发展的现象日益突出,超药品说明书用药(OLDU)发生率较高。OLDU在临床实践工作中普遍存在,在满足临床治疗需求、填补治疗空白的同时,也引发了一些用药相关问题。临床实践中如何规范、安全地OLDU是一个亟待解决的难题。《山东省超药品说明书用药专家共识》(2022版)中收录的肾内及风湿免疫类药物均来自临床实践,提供了详实的循证证据和推荐意见,以期为临床用药提供参考依据。With the rapid development ofthe diagnosis and the treatment of rheumatic immune diseases,especially the emergence of new immunosuppressive drugs has created a new pattern for the clinical treatment of immune diseases.At the same time,the phenomenon that the update of drug label in this field lags behind the development of clinical practice is increasingly prominent,and the incidence of off-label drug use(OLDU)is relatively high.OLDU is prevalent in clinical practice.While meeting the needs of clinical treatment and filling therapeutic gaps,it also causes some medication-related problems.The standardization and safety of OLDU in clinical practice is an urgent problem to be solved.All the OLDU of intrarenal and rheumatic immune drugs included in the Expert Consensus on Off-Label Drug Use in Shandong Province(2022 Edition)are derived from clinical practice,providing detailed evidence-based evidence and recommendations,with a view to providing important reference for clinical use of drugs.

关 键 词：超药品说明书用药 肾内及风湿免疫类药物 循证药学 专家共识 用药目录 

分 类 号：R95[医药卫生—药学]